UOC
EWTX icon

UBS O'Connor’s Edgewise Therapeutics EWTX Stock Holding History

UBS O'Connor’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,000
Closed -$4.88K – 381
2024
Q4 		$4.88K Sell
15,000
-20,000
-57% -$637K ﹤0.01% 405
2024
Q3 		$20.1K Buy
+35,000
New +$696K ﹤0.01% 447

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS O'Connor's EWTX Position: Q3 2025 in Review

UBS O'Connor sold out of Edgewise Therapeutics (EWTX) in Q3 2025, closing a stake of 55,292 shares — an estimated $725K sold.

UBS O'Connor first reported a position in EWTX in Q2 2022 and held it in 12 quarters. The position peaked at $1.53M in Q2 2024. 173 funds tracked by Wall St. Rank hold EWTX as of Q3 2025.

  • UBS O'Connor reported no remaining Edgewise Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 55,292 Edgewise Therapeutics shares in Q3 2025, an estimated $725K.
  • UBS O'Connor first reported a position in Edgewise Therapeutics in Q2 2022 and held it in 12 quarters.
  • UBS O'Connor's Edgewise Therapeutics position peaked at $1.53M in Q2 2024.
  • 173 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.